Comparative evaluation of efficacy and safety of ciprofloxacin and norfloxacin ophthalmic solutions

European Journal of Ophthalmology

Volumn 6, Issue 3, 1996, Pages 287-292

  Adenis, J P ^a   Brasseur, G ^b   Demailly, Ph ^c   Malet, F ^d   Verin, Ph ^e   Saint Blancat, P ^a   Retout, A ^b   Olle P ^b   Colin, J ^d  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c SAINT JOSEPH HOSPITAL   (France)

^d CHU MORVAN   (France)

^e Centre Jean Abadie CHU de Bordeaux   (France)

Author keywords

Blepharitis; Ciprofloxacin; Conjunctivitis; Norfloxacin; Ocular infection

Indexed keywords

CIPROFLOXACIN; NORFLOXACIN;

ADULT; AGED; ARTICLE; BLEPHARITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EYE INFECTION; EYE IRRITATION; FEMALE; HUMAN; KERATITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0029858691     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067219600600312     Document Type: Article

References (26)

1. Campoli-Richards DM, Monk JR, Price A, Banfield P, Todd PA, Ward A. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988; 35: 373-447.
2. Crumplin GC, Kenwright M, Hirst T. Investigations into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother 1984; 13 (suppl B): S9-S23.
3. Janknegt R. Fluorinated quinolones: a review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy. Pharm Weekbl Sci Ed 1986; 8: 1-21.
4. Auckenthaler R, Michéa-Hamzehpour M, Pechère JC. In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother 1986; 17 (suppl B): S29-S39.
5. Neu HC. Microbioiogic aspects of fluoroquinolones. Am J Ophthalmol 1991; 112: 15-24.
6. Steinert RF. Current therapy for bacterial keratitis and bacterial conjunctivitis. Am J Ophthalmol 1991; 112: 10-145.
7. Power WJ, Collum LMT, Easty DL, et al. Evaluation of efficacy and safety of ciprofloxacin ophthalmic solution versus chloramphenicol. Eur J Ophthalmol 1993; 2: 77-82.
8. Pecori Giraldi J, Grechi G, Anania A, Filadoro P, Miglionini RA. La ciprofloxacina per via topica nel trattamento delle affezioni oculari esterne: sua efficacia e tollerabilità. Proc. II Congress of Ocular Pharmacology, Catania 1990.
9. Adenis JP, Colin J, Verin P, Saint-Blancat P, Malet F. Ciprofloxacin ophthalmic solution vs rifamycin ophthalmic solution for the treatment of conjunctivitis and blepharitis. Eur J Ophthalmol (in press).
10. Bloom PA, Leeming JP, Power W, Laidlaw DAH, Collum LMT, Easty DL. Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. Eur J Ophthalmol 1994; 4: 6-12.
11. Cagle G, Davis S, Rosenthal RA, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res 1981; 1: 523-34.
12. Cagle GD, Abshire RL. Quantitative ocular bacteriology: a method for the enumeration and identification of bacteria from the skin-lash margin and conjunctiva. Invest Ophthalmol Vis Sci 1981; 20: 751-7.
13. Baum J, Barza M. Infections of the eye and adjacent sinuses. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: WB Saunders/Harcourt Brace Jovanich Inc, 1992; 1134-51.
14. Smolin G, Okumoto M Staphylococcal blepharitis. Arch Ophthalmol 1977; 95: 812-6.
15. Baum JL. Current concepts in ophthalmology. Ocular infections. N Engl J Med 1978; 6: 28-31.
16. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol 1984; 68: 524-8.
17. Stemert RF. Current therapy for bacterial keratitis and bacterial conjunctivitis. Am J Ophthalmol 1991; 112: 10S-145.
18. Lorian V, Atkinson B. Bacterial resistance to antibiotics in the United States. Ten million strains, nine species and sixteen antibiotics. Drugs Exp Clin Res 1987; 13: 457-77.
19. Mahajan VM. Acute bacterial infections of the eye; their aetiology and treatment. Br J Ophthalmol 1983; 67: 191-4.
20. French GL, Ling J, Ling T, Hui YW. Suscectibility of Hong Kong isolates of methicillin-resistant Staphylococcus aureus to antimicrobial agents. J Antimicrob Chemother 1988; 21: 581-8.
21. Abrams SM, Degnan TJ, Vinciguerra V. Marrow aplasia following topical application of chloramphenicol eye ointment. Arch Intern Med 1980; 140: 576-7.
22. Fraunfelder FT, Bagby GC, Kelly DJ. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982; 93: 356-60.
23. Goldstein EJ, Citron DM, Bendan L, et al. Potential of topical norfloxacin therapy. Arch Ophthalmol 1987; 105: 991-4.
24. Callegan MC, Hill JM, Insler MS, Hobden JA, O'Callaghan RJ. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. Curr Eye Res 1992; 11: 1111-9.
25. Speciale A, Blandino G, Pellegrino MB, Borghi P, Caccamo F. In vitro activity of ciprofloxacin against aminoglycoside-sensitive and resistant Gram-negative rods. Chemioterapia 1986; 5: 196-9.
26. Smith SM, Eng RH, Berman E. The effect of ciprofloxacin on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1986; 17: 287-95.